Võrdle meetodeid
Vaata valitud meetodeid kõrvuti; erinevad read on esile tõstetud.
| SCORADi indeks (SCORing Atopic Dermatitis)× | POEM (patsiendi hinnang atoopilise dermatiidi raskusastmele)× | |
|---|---|---|
| Valdkond | Dermatoloogia | Dermatoloogia |
| Perekond | Process / pipeline | Process / pipeline |
| Tekkeaasta≠ | 1993 | 2004 |
| Looja≠ | European Task Force on Atopic Dermatitis (ETFAD) | Charman CR, Venn AJ, Williams HC |
| Tüüp≠ | Clinician-rated | Self-report |
| Algallikas≠ | Kunz B, Oranje AP, Labrèze L, et al. Clinical validation and guidelines for the SCORAD index: consensus report of the European Task Force on Atopic Dermatitis. Dermatology. 1997;195(1):10-19. DOI ↗ | Charman CR, Venn AJ, Williams HC. The Patient-Oriented Eczema Measure: development and initial validation of a new tool for measuring atopic eczema severity from the patients' perspective. Arch Dermatol. 2004;140(12):1513-1519. DOI ↗ |
| Rööpnimetused | SCORAD Index | POEM Score |
| Seotud≠ | 3 | 2 |
| Kokkuvõte≠ | The SCORAD is a comprehensive clinician-administered tool for measuring the extent and severity of atopic dermatitis (eczema). Developed by the European Task Force on Atopic Dermatitis in 1993, it combines objective clinical assessment with subjective symptom reporting. It is the gold standard for atopic dermatitis severity in clinical trials and dermatology practice. | The POEM is a brief, patient-administered severity measure for atopic dermatitis that focuses on frequency of symptoms experienced over the past week. Developed by Charman, Venn, and Williams in 2004, it emphasizes the patient's lived experience rather than clinician observation, making it practical for routine clinical practice and remote monitoring. POEM is increasingly used alongside objective measures in clinical trials and outpatient care. |
| ScholarGateAndmestik ↗ |
|
|